@MaggiexKara Hottie, YES—I just love HER FACE!! ❤️

🧬 Aptevo Therapeutics $APVO: 100% Remission in Cohort 3 Reinforces Mipletamig’s Differentiated Position in AML Aptevo announced a 100% remission rate (CR/CRi) in Cohort 3 of its RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in

@MaggiexKara 😘

@MaggiexKara ❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️